AUTHORS
Jessica Allen, MD, Geoffrey Shouse, DO PhD2, Cassandra Duarte, MD3, Yun Choi, MD4, Jess Hatfield, MD5, Zain El-amir, MD6, Ly V Do, MD7, Kanithra Sekaran, MD8, Keshav Raghavendran9, Megan Melody, MD, MS10, Taylor Kujawa, PharmD11, Yasmin H Karimi, MD12, Priyanka A. Pophali, MD13, Reem Karmali, MD14, Joanna M Rhodes, MD, MSCE15, Mengyang Di, MD, PhD16, Praveen Ramakrishnan Geethakumari, MD, MS, MBA, FACP17, John L Vaughn, MD, MS18, Yazeed Sawalha, MD19, Natalie S Grover, MD20, Adam J. Olszewski, MD21, Narendranath Epperla, MD, MS, FACP22
AFFILIATIONS
1 Huntsman Cancer Institute, Salt Lake City, Utah, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 University of Colorado Hospital, Aurora, Colorado, United States
4 Ohio State University, Columbus, Ohio, United States
5 Unc Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 University of Wisconsin-Madison, Madison, Wisconsin, United States
8 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
9 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
10 Tgh Cancer Institute, Tampa, Florida, United States
11 Huntsman Cancer Institute, Salt Lake City, Utah, United States
12 University of Michigan, Ann Arbor, Michigan, United States
13 University of Wisconsin-Madison, Madison, Wisconsin, United States
14 Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
15 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
16 Fred Hutch Cancer Center, Seattle, Washington, United States
17 UT Southwestern, Dallas, Texas, United States
18 NYU Langone Hospital Long Island, Mineola, New York, United States
19 Ohio State University, Columbus, Ohio, United States
20 Unc Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
21 Brown University, Providence, Rhode Island, United States
22 Huntsman Cancer Institute, Salt Lake City, Utah, United States
ABSTRACT
Introduction
The introduction of Bruton tyrosine kinase inhibitors (BTKis) has expanded treatment options for relapsed/refractory (R/R) marginal zone lymphoma (MZL). In clinical trials, second-generation BTKis acalabrutinib and zanubrutinib achieved overall response rates (ORR) of 53%–68% and complete response rates (CRR) of 13%–26%, and while zanubrutinib is the only BTKi currently approved by the FDA for use in the US in MZL, acalabrutinib is commonly prescribed off label. Although emerging real-world data supports the effectiveness of zanubrutinib, real-world evidence for acalabrutinib remains limited. We therefore evaluated the real-world effectiveness and tolerability of acalabrutinib in patients with MZL.
Methods
This is a multicenter (14 US sites), retrospective study of adults with MZL diagnosed between 2010 and 2024 who received novel agents including BTKis, lenalidomide, and cellular therapies in any line of therapy (LOT). Baseline characteristics were summarized descriptively. Endpoints included response rates (ORR and CRR), progression-free survival (PFS) and overall survival (OS). Unadjusted and adjusted (propensity score matched [PSM] in a 1:2 ratio) analysis was performed to assess outcomes associated with acalabrutinib and zanubrutinib.
Response rates were assessed using the Lugano criteria. ORR and CRR were compared by LOT using Fisher's exact test and reported 95% confidence intervals (CI); these analyses were considered descriptive because of the small sample size. PFS and OS were estimated using the Kaplan–Meier method, with descriptive subgroup comparisons performed using the log-rank test and proportional hazards models.
Results
Among the 207 patients with MZL receiving novel agents in the dataset, 35 patients received acalabrutinib. The median age at start of acalabrutinib was 73 years (range 44-91). Twenty-three patients (66%) were male. At diagnosis, 31(94%) had ECOG PS of 0-1, 26 (74%) had stage III/IV disease, 5 (14%) had B symptoms, 9 (26%) had elevated LDH, and 4 (11%) had Ki-67 ≥20%. Fifteen (43%) had extranodal MZL (EMZL), 9 (26%) had nodal MZL (NMZL), 8 (23%) had splenic MZL (SMZL), and 3 (9%) had MZL not otherwise specified (NOS). Eleven (31%) had disease refractory to first-line therapy. The median number of prior lines of treatment was 2. Three (9%) patients received acalabrutinib in 1st line, 14 (40%) in 2nd line, 14 (40%) in 3rd line, and 4 (11%) in 4th line and beyond.
Among patients with response evaluable data (n=30), the ORR was 87% (95% CI, 69?96) and the CRR was 33% (95%CI, 17?53). There was no significant difference in ORR or CRR by line of treatment or by MZL subtype, with responses seen in all 8 patients with SMZL (including 5 with recorded CR) and 9 with NMZL.
At a median follow-up of 50.1 months, the median PFS was 30.8 months (95%CI, 11.7?not reached [NR]), and median OS was 54.0 months (95%CI, 44.9?NR). The estimated 24-month PFS and OS were 54% (95%CI, 39?74) and 75% (95%CI, 62?92), respectively. There was no difference in PFS rates by line of treatment (p=0.78), CR versus PR (p=0.86), or by MZL subtype (p=0.88).
We then compared the outcomes of patients receiving acalabrutinib and zanubrutinib (n=116 in our dataset). The 24-month unadjusted PFS rates in those receiving acalabrutinib versus zanubrutinib were 50% versus 67%, respectively (p=0.056). In a model stratified by LOT, acalabrutinib was not associated with a significantly different risk of progression or death compared with zanubrutinib (HR=1.52, 95% CI, 0.88–2.63, p=0.138). After adjustment for available confounders with PSM, the hazard ratio was 1.31 (95% CI=0.66-2.61) for acalabrutinib versus zanubrutinib (p=0.445).
Seven patients (20%) discontinued acalabrutinib due to toxicity, and three had dose reductions without discontinuation. The most common reasons for discontinuation or dose reduction were shortness of breath, pneumonitis, arthralgias, and hepatitis.
Discussion
In this multicenter real-world study, acalabrutinib demonstrated durable clinical activity in patients with MZL, with effectiveness comparable to that observed in clinical trials across LOT and disease subtypes. The prolonged follow-up and median PFS of nearly 3 years provide important evidence supporting the sustained benefit of acalabrutinib. Future studies should evaluate BTKi–based combination regimens to further improve outcomes while carefully balancing efficacy with safety and tolerability.
DISCLOSURES
Jessica Allen, MD: No relevant conflicts of interest to declare.